PAIN-MND survey seeks UK clinicians’ experiences of pain care

University of Sheffield researchers are inviting UK healthcare professionals to complete a survey on physical pain assessment and management in motor neurone disease (MND). The PAIN-MND survey takes approximately 15 minutes and closes on Friday 18 December 2026. Led by Dr Haris Stavroulakis and funded by the MND Association, the survey is the first stage…

US FDA approves asundexian for secondary stroke prevention

The US Food and Drug Administration (FDA) approved asundexian (Sunharbo) on 9 November 2026 to reduce stroke risk in adults after a recent mild to moderate non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack (TIA). It is the first approved factor XIa inhibitor and is used alongside antiplatelet therapy. Bayer reported a separate approval…

Epilepsy linked to higher risk of young-onset dementia

People with epilepsy were more likely to be diagnosed with dementia before age 65 in a study of national health records from France and Sweden. Over 10 years in the French cohort, young-onset dementia was diagnosed in 2.2% of people with newly diagnosed epilepsy, 1.7% of those with established epilepsy and 0.2% of those without…

Long COVID symptoms improved in around half of US cohort by three years

About half of adults who met research criteria for long COVID one year after their first SARS-CoV-2 infection fell below the study’s symptom threshold by year three. Around a quarter reached a score of zero on the study’s symptom index, according to a prospective US cohort study. The study, published online in Annals of Internal…

FDA authorises eShunt study in early Alzheimer’s disease

The US Food and Drug Administration (FDA) has granted CereVasc an Investigational Device Exemption to study its eShunt System in people with early symptomatic Alzheimer’s disease. The authorisation allows the company to begin a clinical investigation of the implant for this indication. The eShunt System is a minimally invasive endovascular implant designed to divert cerebrospinal…

UK guidance published for Alzheimer’s blood biomarker testing

A new expert consensus statement has been published in the journal Practical Neurology, providing recommendations for the appropriate use of blood-based biomarkers in the diagnosis of Alzheimer’s disease. The guidance was developed by specialists representing the Association of British Neurologists and the Royal College of Psychiatrists, with support from Alzheimer’s Research UK and Alzheimer’s Society….

Longer reproductive lifespan and hormone use associated with better brain health

A longer reproductive lifespan and a history of using birth control pills or menopausal hormone therapy were associated with certain signs of blood vessel health in the brain, according to a study published November 4, 2026, in Neurology®, the medical journal of the American Academy of Neurology.   Cerebral small vessel disease affects tiny blood vessels…

New European guidelines published for diagnosis and management of infectious encephalitis

The European Academy of Neurology (EAN) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) have published updated guidelines for diagnosing and managing infectious encephalitis in adults, emphasising the importance of rapid diagnosis, early treatment and ongoing rehabilitation. Infectious encephalitis is a potentially life-threatening condition associated with significant mortality and long-term neurological complications….

Mayo Clinic reports early results from personalised gene-targeted ALS therapy

Researchers at Mayo Clinic have reported encouraging early findings from an experimental treatment developed for a patient with a rare genetic form of amyotrophic lateral sclerosis (ALS). The single-patient study, published in the journal Med, explores how therapies designed to address specific disease-causing mutations could advance precision medicine for people with rare neurological disorders. The…

FDA approves first gene therapy for children with Sanfilippo syndrome type A

The US Food and Drug Administration (FDA) has approved Fayuvi (rebisufligene etisparvovec-hopf), the first approved treatment for children with mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome type A. The gene therapy offers a new treatment option for this rare, inherited neurodevelopmental disorder, which causes progressive neurological deterioration and loss of developmental abilities….